Protocol Ledger

NCT06290128 · Phase III · ACTIVE NOT RECRUITING

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

Interventional Phase III clinical trial protocol NCT06290128 sponsored by Sanofi in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-12 Enrollment: 109 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06290128
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)109 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06290128
Protocol FieldVerified Registry Value
NCT IdentifierNCT06290128
Consolidated Lead SponsorSanofi
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment109 participants (ACTUAL)
Registered Start Date2024-07-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI